Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates (RCCA), discusses how data analytics have improved RCCA’s revenue cycle.
Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates (RCCA), discusses how data analytics have improved RCCA's revenue cycle.
Transcript
How as data analytics improved your revenue cycle?
Data analytics is a fabulous tool because by collecting data, we know at what point in the revenues cycles we have the problems. So, we know if problems are at various stages and how to address those barriers. Is data analytics ready for prime time? It depends what data comes in. A way to scrub and curate the data as it relates to revenue cycle is needed. A lot of the problems we have in revenue cycle nowadays are handled by highly specialized individuals who have training in billing, coding, insurance verification, benefits verification, and other areas of the revenue cycle.
However, it would be fantastic if we could address with artificial intelligence and big data certain aspects of the revenue cycle, such as insurance verification. We collect insurance information at the first patient visits, but if in between the visits, in the time interval the patient changes insurance, we do now have a mechanism right now to capture that, and I don’t think that artificial intelligence is ready to capture that right now. However, I know there are many software products and many companies that are working diligently to improve that situation.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More